Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $0.41-0.46 for the period, compared to the consensus EPS estimate of $0.43. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $388.90 million.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. JMP Securities assumed coverage on shares of Certara in a report on Thursday, April 4th. They set a market perform rating for the company. Jefferies Financial Group raised their price objective on shares of Certara from $14.00 to $15.50 and gave the company a hold rating in a research report on Friday, March 1st. KeyCorp upgraded shares of Certara from a sector weight rating to an overweight rating and set a $23.00 price objective for the company in a research report on Wednesday, April 10th. SVB Leerink began coverage on shares of Certara in a research report on Monday, February 26th. They issued a market perform rating and a $19.00 price objective for the company. Finally, Leerink Partnrs restated a market perform rating on shares of Certara in a research report on Monday, February 26th. Seven research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and an average price target of $20.06.

Certara Trading Up 0.4 %

NASDAQ CERT traded up $0.07 during trading on Friday, reaching $17.13. 96,499 shares of the stock traded hands, compared to its average volume of 532,812. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -49.00, a price-to-earnings-growth ratio of 1.81 and a beta of 1.61. The stock’s 50-day moving average price is $17.71 and its 200 day moving average price is $16.45. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.28. Certara has a fifty-two week low of $11.81 and a fifty-two week high of $22.65.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The firm had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. Analysts predict that Certara will post 0.29 EPS for the current year.

Insider Buying and Selling at Certara

In other news, SVP Richard M. Traynor sold 6,000 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $18.00, for a total value of $108,000.00. Following the sale, the senior vice president now owns 165,368 shares of the company’s stock, valued at $2,976,624. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Certara news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the transaction, the senior vice president now directly owns 173,524 shares in the company, valued at $3,123,432. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard M. Traynor sold 6,000 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $18.00, for a total transaction of $108,000.00. Following the completion of the transaction, the senior vice president now owns 165,368 shares in the company, valued at $2,976,624. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,427 shares of company stock valued at $405,095. 2.39% of the stock is currently owned by corporate insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.